Skip to main content

Roughly one year after acquiring the Almirall respiratory disease division, British company AstraZeneca inaugurated its first Spanish center focusing on these pathologies in Barcelona this Thursday.  

The multinational corporation’s new Center for Respiratory Medicine will employ 75 specialized professionals, including a group of scientists from Almirall and the company’s own researchers. The researchers’ work will focus on the clinical development of inhaled drugs to treat respiratory diseases, as well as positioning and global strategy. Thus, AstraZeneca is strengthening its presence in Spain and its positioning in the country by adding to its headquarters in Madrid.

Ludovic Helfgott, president of AstraZeneca Espanya, has reiterated the company’s interest in promoting its respiratory division “while also strengthening its position in Spain as a strategic global headquarters. Its research tradition and renowned experts in respiratory diseases make this country the ideal location to develop one of the company’s priority areas,” he explained.

Incorporating the Almirall team into AstraZeneca, according to the president, brings many different benefits: teams that are highly familiar with the COPD (Chronic Obstructive Pulmonary Disease) market; good products and devices; and future drugs.

The British company aims to become the leading provider of innovative inhaled and personalized treatments for asthma, COPD (Chronic Obstructive Pulmonary Disease) and Idiopathic Pulmonary Fibrosis (IPF), and to help tackle unmet medical needs related to these conditions. 

Sign up for our newsletters

Stay up-to-date on the latest news, events and trends in the BioRegion.